Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
Adult
Antioxidants
/ therapeutic use
Atherosclerosis
/ metabolism
Dyslipidemias
/ blood
Enzyme-Linked Immunosorbent Assay
/ methods
Female
Humans
Hyperlipoproteinemia Type II
/ blood
Hypolipidemic Agents
/ pharmacokinetics
Lipoproteins, HDL
/ analysis
Male
Oxidation-Reduction
/ drug effects
Probucol
/ pharmacokinetics
Reproducibility of Results
Apolipoproteins
Familial hypercholesterolemia
HDL
Oxidized lipids
Phospholipids
Journal
Journal of atherosclerosis and thrombosis
ISSN: 1880-3873
Titre abrégé: J Atheroscler Thromb
Pays: Japan
ID NLM: 9506298
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
pubmed:
9
10
2020
medline:
15
12
2021
entrez:
8
10
2020
Statut:
ppublish
Résumé
HDL particles have various anti-atherogenic functions, whereas HDL from atherosclerotic patients was demonstrated to be dysfunctional. One possible mechanism for the formation of dysfunctional HDL is the oxidation of its components. However, oxidized HDLs (Ox-HDLs) remain to be well investigated due to lack of reliable assay systems. We have developed a novel sandwich enzyme-linked immunosorbent assay (ELISA) for Ox-HDL by using the FOH1a/DLH3 antibody, which can specifically recognize oxidized phosphatidylcholine, a major component of HDL phospholipid (HDL-PL). We defined forced oxidation of 1 mg/L HDL-PL as 1 U/L Ox-HDL. We assessed serum Ox-HDL levels of normolipidemic healthy subjects ( n=94) and dyslipidemic patients (n=177). The coefficients of variation of within-run and between-run assays were 12.5% and 13.5%. In healthy subjects, serum Ox-HDL levels were 28.5±5.0 (mean±SD) U/L. As Ox-HDL levels were moderately correlated with HDL-PL (r=0.59), we also evaluated the Ox-HDL/HDL-PL ratio, which represents the proportion of oxidized phospholipids in HDL particles. In dyslipidemic patients, Ox-HDL levels were highly variable and ranged from 7.2 to 62.1U/L, and were extremely high (50.4±13.3U/L) especially in patients with hyperalphalipoproteinemia due to cholesteryl ester transfer protein deficiency. Regarding patients with familial hypercholesterolemia, those treated with probucol, which is a potent anti-oxidative and anti-hyperlipidemic drug, showed significantly lower Ox-HDL (16.2±5.8 vs. 30.2±5.4, p<0.001) and Ox-HDL/HDL-PL ratios (0.200±0.035 vs. 0.229±0.031, p=0.015) than those without probucol. We have established a novel sandwich ELISA for Ox-HDL, which might be a useful and easy strategy to evaluate HDL functionality, although the comparison study between this Ox-HDL ELISA and the assay of HDL cholesterol efflux capacity remains to be done. Our results indicated that probucol treatment may be associated with lower Ox-HDL levels.
Identifiants
pubmed: 33028763
doi: 10.5551/jat.56887
pmc: PMC8265427
doi:
Substances chimiques
Antioxidants
0
Hypolipidemic Agents
0
Lipoproteins, HDL
0
Probucol
P3CTH044XJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
703-715Références
PLoS One. 2014 May 15;9(5):e95925
pubmed: 24830642
J Lab Clin Med. 2003 Jun;141(6):378-84
pubmed: 12819635
Atherosclerosis. 2012 Feb;220(2):463-9
pubmed: 22024277
Curr Opin Lipidol. 2015 Aug;26(4):304-16
pubmed: 26125504
J Am Coll Cardiol. 2005 Nov 15;46(10):1792-8
pubmed: 16286161
Nat Med. 2014 Feb;20(2):193-203
pubmed: 24464187
Nat Rev Cardiol. 2016 Jan;13(1):48-60
pubmed: 26323267
J Atheroscler Thromb. 2008 Dec;15(6):292-303
pubmed: 19060422
Lancet Neurol. 2018 Jun;17(6):509-518
pubmed: 29778364
Circulation. 2001 Sep 4;104(10):1108-13
pubmed: 11535564
PLoS One. 2018 Jan 5;13(1):e0190875
pubmed: 29304079
Eur Heart J. 2017 Aug 21;38(32):2478-2486
pubmed: 28419274
N Engl J Med. 2011 Jan 13;364(2):127-35
pubmed: 21226578
N Engl J Med. 2017 May 18;376(20):1933-1942
pubmed: 28514624
J Lipid Res. 2013 Nov;54(11):2950-63
pubmed: 23543772
Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):181-8
pubmed: 26543100
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):481-8
pubmed: 11304461
J Lipid Res. 2013 Oct;54(10):2575-85
pubmed: 23434634
N Engl J Med. 2011 Dec 15;365(24):2255-67
pubmed: 22085343
Clin Biochem. 2000 Jun;33(4):243-53
pubmed: 10936581
J Am Coll Cardiol. 2015 Nov 17;66(20):2201-2210
pubmed: 26564598
J Clin Lipidol. 2019 Mar - Apr;13(2):317-325
pubmed: 30745272
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
J Lipid Res. 2009 Mar;50(3):586-594
pubmed: 18832772
Anal Biochem. 1975 May 12;65(1-2):42-9
pubmed: 165752
J Biol Chem. 1994 May 27;269(21):15274-9
pubmed: 8195164
Circ Res. 2018 Jan 5;122(1):106-112
pubmed: 29018035
Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1053-9
pubmed: 9194754
J Clin Lipidol. 2018 May - Jun;12(3):674-684.e5
pubmed: 29506864
J Biol Chem. 1996 Dec 27;271(52):33208-17
pubmed: 8969177
J Biol Chem. 1998 Mar 13;273(11):6088-95
pubmed: 9497326
J Biochem. 1994 Aug;116(2):257-62
pubmed: 7822240
J Clin Invest. 2007 Mar;117(3):746-56
pubmed: 17332893